HER2-Low Breast Cancer: DESTINY or Good Science?

This informative video sheds light on the nuances of HER2 biomarkers in breast cancer, exploring the critical distinctions between HER2 positive, negative, and the newly recognized HER2-Low category.
Embark on a journey through the history of HER2, from its discovery in the 1980s to the present, where FDA-approved treatments like trastuzumab (Herceptin) and trastuzumab-deruxtecan (ENHERTU) are making significant strides in patient care. Dr. Esteva discusses the pivotal DESTINY B04 clinical trial and its role in shaping the future of breast cancer treatment, highlighting the science behind the success of innovative therapies, including the concept of antibody-drug conjugates for HER2-positive and HER2-Low breast cancer.
Disclaimer: This video presents my views and perspectives, which are not necessarily representative of the opinions of my associated employers or institutions. The content provided herein is intended solely for informational purposes and should not be construed as medical advice. I endeavor to ensure the accuracy and timeliness of the information contained in this video. However, for personalized medical advice and guidance, it is recommended to seek consultation with a qualified healthcare professional.
Keywords: HER2-Low Breast Cancer, HER2 Biomarkers, Trastuzumab, Herceptin, ENHERTU, FDA Approval, DESTINY B04, Oncology, Breast Cancer Treatment, Antibody-Drug Conjugates, Medical Oncology
Hashtags: #HER2Low, #BreastCancerAwareness, #OncologyInnovation, #Trastuzumab, #ENHERTU
#CancerTreatment, #HER2Positive, #MedicalOncology
#CancerResearch, #DESTINYB04, #DESTINYB06
For more content on cancer treatment updates, please visit my website: www.cancertreatmentupdates.com and subscribe to my CZcams channel: / @cancertreatmentupdates
Follow me:
Instagram / dresteva
Facebook www.facebook.c...
Twitter (X) / cancerrxupdates
TikTok. / dresteva
LinkedIn / franciscoesteva
Google Scholar: scholar.google...
CZcams / @cancertreatmentupdates